Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Systematic Review Sample Work

A systematic review on the efficacy of wearable medical devices in monitoring blood glucose levels in diabetic patients
Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels, which can lead to serious complications such as cardiovascular disease, kidney failure, and blindness. Monitoring blood glucose levels is a critical aspect of diabetes management, as it allows for timely adjustments in medication and lifestyle to maintain optimal glycemic control.

What a two-page review of glucose wearables has to fit in

This sample is a condensed systematic review laid out in two columns, closer to an extended structured abstract than a full journal article. It runs through Introduction, Objective, Methods, Results, an evidence table, Conclusion and References in two pages. A format this short suits conference handouts, internal evidence briefings for diabetes services, or a first draft before a full PRISMA manuscript. Readers such as endocrinologists, diabetes specialist nurses and device researchers want three things quickly: the question, how the evidence was gathered, and whether the findings agree.

From fingerstick testing to continuous and flash monitoring

The introduction describes diabetes mellitus as a chronic metabolic disorder with raised blood glucose, which can lead to cardiovascular disease, kidney failure and blindness. Monitoring allows medication and lifestyle to be adjusted. The review explains that fingerstick testing is often seen as inconvenient, and that this contributes to poor adherence. Continuous glucose monitors (CGMs) and flash glucose monitoring systems are presented as alternatives that give real-time readings. The review frames its question around uncertainty: whether these wearables actually improve glycaemic control is still unclear, so the evidence needs to be gathered in one place.

Search, screening and appraisal decisions in the sample

  • Databases: PubMed, Embase and the Cochrane Library, covering studies published from 2010 to 2022.
  • Eligibility: studies of wearable devices used to monitor blood glucose in people with diabetes; non-English studies excluded.
  • Extraction: two reviewers working independently with a standardised form, recording design, sample size, device, duration, outcomes and key findings.
  • Quality assessment: the Cochrane risk-of-bias tool for randomised controlled trials and the Newcastle-Ottawa Scale for non-randomised studies.
  • Synthesis: narrative rather than statistical pooling.

The search found 15 eligible studies: six RCTs, five prospective cohorts and four retrospective cohorts. They were conducted in the United States, Europe and Asia and included 2,500 patients in total.

Reading the evidence table row by row

The table summarises five of the included studies, and each row has a different primary outcome:

StudyDesign (n)Device, durationOutcome and finding
1RCT (200)CGM, 6 monthsHbA1c fell significantly versus control
2Prospective cohort (300)Flash monitoring, 12 monthsImproved glycaemic control
3Retrospective cohort (150)CGM, 3 monthsFewer hypoglycaemic events
4RCT (180)Flash monitoring, 9 monthsBetter quality of life
5Prospective cohort (250)CGM, 6 monthsHigher adherence to monitoring

The results are reported in a balanced way. Several studies found lower HbA1c with wearables, but some found no significant difference from traditional monitoring. The conclusion supports wearable use and calls for more work on long-term efficacy and cost-effectiveness.

How the conclusion keeps its claims in proportion

The conclusion is carefully worded. It says the review "provides evidence supporting" efficacy, not that efficacy has been proven. It also states two open questions, long-term efficacy and cost-effectiveness, which the included studies of 3 to 12 months could not answer. The closing recommendation, that clinicians should consider adding wearables to diabetes management protocols, follows from the mixed but generally favourable results without overstating them. A short review needs this restraint, because readers will often quote the conclusion without reading the table.

The reference list uses a numbered Vancouver-style format with abbreviated journal titles, volume, issue and page ranges, which is the usual convention for clinical diabetes journals. If you adapt the sample, check every reference against its source record and confirm that each table row matches the numbered citation it summarises.

What a full PRISMA 2020 version would need to add

Because the outcomes cover HbA1c, hypoglycaemia, quality of life and adherence, a meta-analysis would combine measures that cannot be pooled, so narrative synthesis is the right choice. Expanding the sample into a submission would mean adding the PRISMA 2020 items that a two-page format leaves out:

  • a flow diagram;
  • protocol registration, for example on PROSPERO;
  • full search strings;
  • risk-of-bias judgements for each study;
  • a certainty-of-evidence rating such as GRADE.

Separating type 1 from type 2 diabetes, and CGM from flash devices, would also make the conclusions more precise.

Authors whose outcomes can be pooled can use Pubrica's meta-analysis service, and search strategies can be built through literature search and citation support. Draft reviews can be strengthened through scientific editing. This page is a writing sample, not advice on choosing a glucose monitor.

Questions about this sample

Why does this review use narrative synthesis instead of a meta-analysis?

The included studies measured different outcomes, including HbA1c, overall glycaemic control, hypoglycaemic events, quality of life and adherence, using different devices and follow-up periods from 3 to 12 months. Pooling such different measures into one effect estimate would be misleading, so the findings are summarised and compared in narrative form.

Which quality appraisal tools does the sample name?

The Cochrane risk-of-bias tool for the six randomised controlled trials and the Newcastle-Ottawa Scale for the nine cohort studies. Using a separate tool for each design is standard practice, because randomised and observational studies are open to different sources of bias.

How many studies and patients were included?

Fifteen studies met the inclusion criteria: six randomised controlled trials, five prospective cohorts and four retrospective cohorts. Together they included 2,500 people with diabetes in the United States, Europe and Asia. The evidence table summarises five of these studies in detail.

Does the review distinguish CGM from flash glucose monitoring?

The table does: studies 1, 3 and 5 used CGM, and studies 2 and 4 used flash monitoring. The conclusion, however, treats both as wearable devices. A fuller version could analyse them separately and also split results by diabetes type, since the cited studies cover both type 1 and type 2.

sample-workimage-for-sidebar

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.